At a glance
- Originator Bristol-Myers Squibb
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 18 Jan 2005 Discontinued - Preclinical for HIV infections treatment in USA (PO)
- 13 Feb 2001 Profile reviewed but no significant changes made
- 02 Sep 1998 No-Development-Reported for HIV infections treatment in USA (PO)